Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3057915 | 0.96 | GRIN1 (0.38) | GRIN1GRIN2BGRM2TACR2TACR1 | |
| SCHEMBL3068898 | 0.81 | GRIN1 (0.38) | GRIN1GRIN2BGRM2TACR2TACR1 | |
| SCHEMBL8202220 | 0.81 | GRIN1 (0.39) | GRIN1GRIN2BGRM2TACR2TACR1 | |
| SCHEMBL3073001 | 0.79 | GRM2 (0.44) | GRIN1GRIN2BGRM2TACR2TACR1 | |
| SCHEMBL3068894 | 0.78 | GRIN1 (0.38) | GRIN1GRIN2BGRM2TACR2TACR1 | |
| SCHEMBL8213419 | 0.78 | GRM2 (0.44) | GRIN1GRIN2BGRM2TACR2TACR1 | |
| SCHEMBL8213485 | 0.77 | GRM2 (0.41) | GRIN1GRIN2BGRM2TACR2TACR1 | |
| SCHEMBL3077038 | 0.77 | AOC3 (0.42) | GRIN1GRIN2BGRM2TACR2TACR1 | |
| SCHEMBL13140443 | 0.77 | GRM2 (0.43) | GRIN1GRIN2BGRM2TACR2TACR1 | |
| SCHEMBL8210112 | 0.77 | GRM2 (0.45) | GRIN1GRIN2BGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790717-B2 | administering 3-(4'-Morpholin-4-ylmethyl-biphenyl-4-ylmethyl)-1-oxa-3-aza-spiro[4.5]decan-2-one, for the treatment of schizophrenia | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-20090124578-A1 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124578-A1 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | GRIN1 2/4885GRIN2B 5/4885GRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.